Simulations Plus, Inc. (NASDAQ:SLP) is a leading developer of modeling and simulation software used throughout the pharmaceutical and biotech industries. Founded in 1996 and headquartered in Lancaster, California, the company provides an integrated suite of tools that support preclinical and clinical drug development. By leveraging advanced computational methods, Simulations Plus’ software platforms enable clients to predict absorption, distribution, metabolism, excretion, and toxicity (ADMET) properties of new drug candidates and optimize formulation and dosage strategies before initiating costly laboratory and clinical studies.
The company’s flagship products include GastroPlus for physiologically based pharmacokinetic (PBPK) modeling, DDDPlus for formulation and dissolution simulation, MembranePlus for membrane permeability analysis, and MedChem Studio for molecular design and property prediction. In addition to its core software offerings, Simulations Plus has expanded its capabilities through strategic acquisitions, integrating data analytics and machine learning solutions tailored to streamline decision-making in clinical trial design and regulatory submissions. These tools are widely adopted by major pharmaceutical companies, contract research organizations (CROs), and academic institutions in North America, Europe, and Asia.
Over its history, Simulations Plus has established partnerships with regulatory agencies and scientific consortia to advance best practices in model-informed drug development. The company maintains offices in strategic locations, including the United Kingdom and Switzerland, to better serve an international client base. Under the leadership of founder and Chief Executive Officer Walter Woltosz, along with an experienced executive team, Simulations Plus continues to invest in research and development, aiming to enhance predictive accuracy and accelerate the drug discovery pipeline.
Simulations Plus’ commitment to innovation is reflected in its ongoing collaborations with academic researchers and regulatory authorities to validate and refine simulation methodologies. By combining robust software solutions with domain expertise, the company helps reduce attrition rates in drug development, lower R&D costs, and bring safe, effective therapies to market more efficiently. As the complexity of pharmaceutical research grows, Simulations Plus remains at the forefront, delivering the computational tools necessary for informed decision-making across the entire drug development lifecycle.
AI Generated. May Contain Errors.
Free SLP Stock Alerts